Abstract 371P
Background
Head and neck cancers (HNCs) are a challenging disease to treat due to their anatomical complexity and high propensity for locoregional recurrence. Radiation therapy is a crucial component of treatment approach for HNCs. However, assessing the response to therapy can be difficult, particularly in the early post-treatment period. Positron emission tomography (PET) with the glucose analogue [18F] fluorodeoxyglucose (FDG) has shown promising results in the assessment of treatment response in HNCs. Therefore, this systematic review is written to evaluate the role of FDG-PET/CT in the assessment of response to radiotherapy in HNCs.
Methods
A comprehensive search of electronic databases was conducted, including EMBASE, Scopus, Pubmed, PMC, and Science Direct from inception to April 2023. Studies were included if they reported on the use of FDG-PET/CT for assessing treatment response in HNCs treated with radiation therapy. Quality assessment using Newcastle-Ottawa Scale and data extraction were performed independently by three reviewers.
Results
16 studies reporting on a total of 348 patients were included in this analysis. The data assessed in the included studies were diverse, including the evaluation of the diagnostic performance of FDG-PET/CT, the comparison with conventional imaging techniques, the ability to avoid neck dissections, or assessed which patient population would derive most benefit from post-treatment FDG-PET/CT scan. Despite their diversity, almost all studies have showed that FDG-PET/CT scan is a reliable method to evaluate residual or recurrent tumour within 6 months post-(chemo)radiation therapy with pooled sensitivity of 84% and pooled specificity of 90%. There was a moderate risk of bias due to selection bias. Also, confirmation of positive nodal disease at the time of diagnosis and prior to therapy is an important shortcoming in most included studies.
Conclusions
FDG-PET/CT within 6 months after (chemo)radiotherapy in HNCs patients is a reliable method for ruling out residual/recurrent nodal disease and obviates the need for therapeutic intervention. However, further standardization of the PET technique is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract